1 HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting

- 2 Short title: HIV & HF Phenotypes and Outcomes in a Safety Net System
- 3 Authors: Matthew S. Durstenfeld MD MAS^{1*}, Anjali Thakkar MD MBA^{2*}, Diane Jeon MD
- 4 MS², Robert Short MD³, Yifei Ma MS¹, Zian H. Tseng MD MAS⁴, Priscilla Y. Hsue MD¹
- 5 Affiliations:

8

9

- Division of Cardiology at ZSFG and Department of Medicine, University of California,
 San Francisco (UCSF), USA
 - 2. Division of Cardiology, Department of Medicine, University of California, San Francisco
 - 3. Department of Medicine, University of California, San Francisco
- Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine,
 University of California, San Francisco
- 12 *Contributed equally

13 Address for Correspondence:

- 14 Matthew S. Durstenfeld, MD MAS
- 15 Division of Cardiology, UCSF at Zuckerberg San Francisco General Hospital
- 16 1001 Potrero Avenue, 5G8
- 17 San Francisco, CA 94110, USA
- 18 Tel: +1 628 206 5562; Fax: +1 628 206 5447
- 19 e-mail: matthew.durstenfeld@ucsf.edu
- 20 twitter: @durstenfeld
- 21 Word Count: 3010
- 22 **Tweet:** HIV associated with 55% higher mortality after #HeartFailure diagnosis in the safety-
- 23 net, mainly from non-CVD causes inc. substance-related @durstenfeld @UCSFCardiology
- 24 @UCSF_HIVIDGM @SF_POSTSCD
- 25
- 26 **Disclosures:** None of the authors have pertinent disclosures or relevant conflicts of interest.
- **Funding:** Dr. Durstenfeld is funded by NIH grant NIH/NLBI (K12 HL143961). This work was
- assisted in part by a CFAR-ARI Boost Award from the UCSF AIDS Research Institute and was
- supported by the National Center for Advancing Translational Sciences, National Institutes of
- Health, through UCSF-CTSI Grant Number UL1TR001872. Dr. Tseng is funded by R01
- HL157247 and the autopsy data were funded by R01HL102090. Dr. Hsue is funded by
- K24AI112393. Its contents are solely the responsibility of the authors and do not necessarily
- represent the official views of the NIH.
- 34
- 35

36 Clinical Perspectives

- People with HIV develop heart failure 10 years earlier than people without HIV, with a
 higher proportion with HFrEF at diagnosis.
- HIV is associated with higher mortality among people with heart failure, primarily due to non-cardiovascular causes including HIV/AIDS and substance use.

41 **Research Perspectives**

The reasons for higher mortality in PWH with HF are not yet fully understood; higher
 levels of myocardial fibrosis may predispose people with substance use and advanced
 HIV disease to increased risk of mortality.

46 Abstract

- 47 Background: Human immunodeficiency virus (HIV) is associated with increased risk of heart
- failure (HF) but data regarding phenotypes of heart failure and outcomes after HF diagnosis,
- 49 especially within the safety-net which is where half of people with HIV in the United States
- 50 receive care, are less clear.
- 51 **Methods:** Using an electronic health record cohort of all individuals with HF within a municipal
- safety-net system from 2001-2019 linked to the National Death Index Plus, we compared HF
- 53 phenotypes, all-cause mortality, HF hospitalization, and cause of death for individuals with and
- 54 without HIV.
- **Results:** Among people with HF (n=14,829), 697 individuals had HIV (4.7%). Persons with HIV
- 56 (PWH) were diagnosed with HF ten years younger on average. A higher proportion of PWH had
- a reduced ejection fraction at diagnosis (37.9% vs 32.7%). Adjusted for age, sex, and risk
- 58 factors, coronary artery disease on angiography was similar by HIV status. HIV was associated
- with 55% higher risk of all-cause mortality (HR 1.55; 95% CI 1.37-1.76; P<0.001) and lower
- odds of HF hospitalization (OR 0.51; 95% CI 0.39-0.66; P<0.001). Among PWH with HF, cause
- of death was less often attributed to cardiovascular disease (22.5% vs 54.6% uninfected;
- 62 P<0.001) and more to substance use (17.9% vs 9.3%; P<0.001), consistent with autopsy findings
- 63 in a subset (n=81).
- 64 **Conclusions:** Among people with HF who receive care within a municipal safety-net system,
- 65 HIV infection is associated with higher mortality, despite lower odds of HF hospitalization,
- 66 attributable to non-cardiovascular causes including substance-related and HIV-related mortality.
- 67
- 68 Key Words: HIV, Heart Failure, Clinical Outcomes, Mortality
- 69 Abbreviations: HF=Heart Failure; HFrEF=Heart Failure with Reduced Ejection Fraction;
- 70 HIV=Human Immunodeficiency Virus; PWH=persons with HIV.

71 Introduction

72	Human immunodeficiency virus (HIV) infection is associated with increased risk of heart
73	failure (HF), even in the absence of coronary artery disease, with the highest risk among those
74	with higher viral load and lower CD4 counts (1-3). The prevalence of clinical heart failure
75	among persons with HIV (PWH) is estimated to be 6.5%, with higher rates of subclinical LV
76	systolic and diastolic dysfunction (4). Prior studies within tertiary referral centers and the
77	Veterans Affairs system found that PWH with HF have higher risk of HF hospitalization and
78	mortality compared to people with HF without HIV (5-7). In contrast, among people with
79	incident HF within the Kaiser Permanente integrated care system, HIV was associated with all-
80	cause mortality but not HF hospitalizations or Emergency Department visits (8). Over half of
81	PWH in the United States receive benefits through the Ryan White HIV/AIDS Program, the
82	federal safety-net program for PWH. Outcomes reported within tertiary referral centers or
83	integrated care systems may not generalize to the majority of PWH in the United States.
84	Therefore, we sought to describe heart failure phenotypes, treatment, outcomes after HF
85	diagnosis among PWH compared to people with HF without HIV within a safety-net system with
86	particular attention to mortality, HF hospitalization, and cause of death.

87 Methods

Study Design & Population 88

89 This study was an electronic health record-based cohort study of all individuals with HF who received care within the San Francisco Health Network, the public, municipal safety-net 90 health system of San Francisco, California from April 2001-July 2019. 91

92 Exposure

93	The primary exposure was infection with HIV prior to diagnosis with HF. HF was
94	manually adjudicated by review of a random subset of EHR records and found to be 97%
95	specific for possible HF and 94% specific for definite HF. We initially classified people with
96	HIV using International Classification of Diseases (ICD-9 or ICD-10) codes alone, but by
97	manual adjudication the specificity was only 60%; 40% were false positives without HIV. To
98	increase specificity, we further classified only those with and ICD code and at least one CD4
99	count or viral load result as HIV+ which increased the manually adjudicated specificity to 99.8%
100	while maintaining 100% sensitivity among adjudicated charts (0 false negatives among 45
101	adjudicated with HIV ICD codes and neither CD4 nor viral load).
102	Outcomes
103	The primary outcome was all-cause mortality. To ascertain mortality, we matched
104	individuals with the National Death Index and Social Security Death Index using names, date of
105	birth, and social security numbers. For individuals matched and alive, we censored them at the
106	last search date (12/31/2019). For unmatched individuals, we used the last EHR contact date and
107	recorded vital status. Among known deaths, we linked records with the POstmortem Systematic
108	Investigation of Sudden Cardiac Death (POST SCD Study), an ongoing prospective post-mortem
109	study of presumed (WHO-defined) sudden cardiac deaths in San Francisco (9,10).
110	Our secondary goals were to characterize HF phenotypes by HIV status including
111	echocardiographic findings (left ventricular systolic function, pulmonary artery systolic pressure
112	or pulmonary hypertension, and valvular disease) and angiography results (obstructive coronary
113	artery disease defined as \geq 80% stenosis in a major epicardial vessel or \geq 50% left main stenosis).
114	Covariates

Medical history was obtained from ICD codes available at the time of HF diagnosis with a 1-year look-back period. Ambulatory medications were obtained from hospital admission and discharge medication reconciliation and thus were not available for those who were not hospitalized. Echocardiographic and cardiac catheterization results were obtained through structured text extraction from clinical reports with manual adjudication and correction of discrepancies. The primary underlying cause of death was extracted from death certificate data and classified based on ICD codes.

122 Statistical Analysis

We described differences by HIV status using chi-squared tests for categorical variables 123 (and Fisher's exact test for autopsy data given limited numbers), t-tests for normally distributed 124 125 continuous variables, and Wilcoxon rank sum tests for non-normally distributed continuous variables. We used Cox proportional hazards models to estimate adjusted hazard ratios for 126 mortality with censoring for loss of follow up. We used directed-acyclic graphs and expert 127 knowledge to decide potential measured confounders (namely, those potentially associated with 128 risk of HIV and with HF outcomes), such that we included age by sex interaction terms, 129 race/ethnicity, and substance use (alcohol, tobacco, cocaine, methamphetamine, opioids) in 130 adjusted models. Although more likely to be mediators than confounders, given differences in 131 past medical history by HIV status we conducted sensitivity analyses including hypertension, 132 133 diabetes, chronic kidney disease, COPD, liver disease, and cancer. We conducted additional sensitivity analyses considering HIV variables (CD4 count, viral load), Hepatitis C co-infection, 134 135 and secular trends (pre and post 2011).

136 *Approval*

Durstenfeld et al. HIV & HF Phenotypes and Outcomes in a Safety Net System

The University of California San Francisco Institutional Review Board approved this
study and granted a waiver of consent. Results are reported in accordance with the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

140 **Results**

Among those with HF (n=14,829), 906 (6.1%) individuals an ICD code for HIV and 697 (4.7%) had HIV by ICD code and at least one CD4 count and/or viral load measured. Median follow up was 3.5 years after diagnosis with HF (IQR 0.9, 8.3). On average, PWH were 10 years younger at diagnosis. Compared to people without HIV with HF, a higher proportion of PWH were male and had documented substance use (Table 1, p<0.001 for each). Among PWH, the median nadir CD4 count was 133 (IQR 44, 275), and CD4 count at HF diagnosis was 356 (IQR 173, 566).

148 Echocardiographic Findings

149 Among those with HF, 593 PWH (85%) and 10,579 without HIV (75%) completed at least one transthoracic echocardiogram linked to their EHR record (Table 2). Using an LVEF 150 cutoff of 40% (or moderately reduced if LVEF was missing) on the first echocardiogram after 151 152 diagnosis, 225 (37.9%) of PWH had HF with reduced ejection fraction (HFrEF) compared to 2,465 (32.7%) without HIV (p=0.009). The proportion with severely reduced LVEF did not 153 differ significantly by HIV status: 23.0% with HIV versus 20.7% without HIV (p=0.59 for 154 ordinal comparison). Mean LVEF and pulmonary artery systolic pressure at diagnosis were 155 156 similar between groups (p=0.13 and p=0.77, respectively). A higher proportion with HIV had 157 severe mitral regurgitation (10.5% with HIV vs 6.8% without; p=0.01), but other valvular 158 disease including endocarditis did not vary by HIV status.

159 Ischemic vs Nonischemic Cardiomyopathy

160	By HIV status, a similar proportion had prior myocardial infarction documented (12.1	
161	PWH vs 14.7% without HIV, p=0.06). Likewise, a similar proportion without prior	
162	revascularization completed coronary angiography: 140 (20%) with HIV and 2,714 (19%)	
163	without HIV. Angiographic severity of coronary artery disease did not vary by HIV status	
164	(p=0.17, Table 1). Adjusted for age, sex, race/ethnicity, comorbidities, and substance use, there	
165	remained no difference in angiography results (OR 0.97; 95% CI 0.70-1.34; p=0.87). HIV was	
166	not associated with differences in the proportion revascularized (10.2 vs 9.9%; OR 1.12; 95% C	ľ
167	0.86-1.46; p=0.39) or revascularization strategy (coronary artery bypass graft surgery versus	
168	percutaneous coronary intervention; p=0.66).	
169	HF Admission, Medical Therapy, and Device Therapy among those Hospitalized for Heart	
170	Failure	
171	A lower proportion of PWH were hospitalized for HF compared to people without HIV	
172	(7.7% versus 11.3%, p=0.001). HIV was associated with lower adjusted odds of HF	
173	hospitalization (OR 0.51; 95% CI 0.39-0.66; p<0.001). HIV was not associated with all-cause	
174	readmission (OR 0.96; 95%I 0.55-1.67; p=0.89) and there was a trend toward lower odds of HF	1_
175	specific readmission (OR 0.56; 95%CI 0.31-1.01; p=0.06). Among those with HFrEF who were	•
176	hospitalized, HIV was associated with higher prescription of HF guideline-directed medical	
177	therapy defined as at least one of angiotensin-converting enzyme inhibitor, angiotensin receptor	•
178	blocker, beta blocker, or mineralocorticoid receptor antagonist (53% vs 39%; OR 2.13 95% CI	
179	1.08-4.21; p=0.03). HIV was associated with similar rates of statin prescription that was not	
180	statistically significant after adjustment (35% vs 27%; OR 1.77; 95%CI 0.91-3.44; p=0.09).	
181	PWH were also more likely to have outpatient follow up within 30 days of HF discharge (80%	
	Durstenfeld et al. HIV & HF Phenotypes and Outcomes in a Safety Net System	8

vs 65%, p=0.001). Only four PWH had defibrillators implanted, two each for primary and
secondary prevention: one each were for cardiac resynchronization therapy.

184 *Mortality*

185	In total, 41% died before the end of follow-up time including 354 (50.8%) with HIV and
186	5,784 (40.9%) without HIV (p<0.001). HIV was associated with higher age-, sex-, and substance
187	use-adjusted risk of all-cause mortality (HR 1.55; 95%CI 1.37-1.76; p<0.0001; Central
188	Illustration). The median survival after HF diagnosis was 6.1 years (95% CI 5.4-7.1 years)
189	among PWH compared to a median survival of 11.3 years (95% CI 10.7-11.7) years among
190	people without HIV. The higher risk remained elevated among PWH accounting for past medical
191	history (HR 1.37; 95% CI 1.22-1.54; p<0.001). Results were similar for 1-year mortality with
192	adjusted relative risk ratios of 1.72 (95% CI 1.50-1.97) adjusted for age, sex, and substance use,
193	and 1.47 (95% CI 1.28-1.70) additionally accounting for past medical history. The absolute risk
194	difference in 1-year mortality among those with HIV compared to without HIV was 11.0% (95%
195	CI 7.5%-14.4%) and 7.3% (95% CI 4.1-10.4) accounting for other past medical history.
196	Both lower nadir CD4 and lower CD4 at the time of HF diagnosis were associated with
197	worse survival among PWH: HR 1.37 for nadir CD4 count < 200 (95% CI 1.08-1.75; p=0.009)
198	and HR 1.69 for current CD4 count<200 (95% CI 1.34-2.13; p<0.001), respectively. Viral load
199	less than 500 copies/ml was not associated with mortality (HR 1.02; 95%CI 0.80-1.31; p=0.87).
200	There was not a significant interaction with Hepatitis C coinfection (p _{interaction} =0.53). Restricting
201	the PWH to only those virally suppressed (<75 copies per milliliter, n=76) compared to people
202	without HIV yielded similar adjusted hazard for mortality (HR 1.52, 95% CI 1.27-1.83;
203	p<0.001).

204	In an exploratory analysis to consider secular trends, we divided the study into 2001-2010
205	and 2011-2019. Among those diagnosed with HF more recently, HIV was associated with a
206	smaller increase in mortality relative to people without HIV (HR 1.24, 95% CI 1.02-1.51;
207	p=0.03) compared to before 2011 (HR 1.75, 95% CI 1.52-2.01, p<0.001, p _{interaction} =0.004).
208	By death certificate data (n=3650, 262 PWH), there were notable differences by HIV
209	status (Figure 1). Among PWH, 36% had the primary underlying cause of death classified as
210	HIV/AIDS-related, 19% as cardiovascular, 16% as due to accident/injury (including overdose).
211	Among those without HIV, 46% of deaths were attributed to cardiovascular causes, 11% to
212	neoplasms and blood disorders, and only 8% to accidents, injuries, and overdoses. PWH had
213	twice the odds of cause of death attribution to overdose or substance use (OR 2.1; 95% CI 1.53-
214	3.00; p<0.001), but not after accounting for age, sex, and documented history of substance use
215	(OR 0.96; 95% CI 0.67-1.37; p=0.82). In contrast, HIV was associated with lower odds of
216	having cardiovascular disease as the primary recorded cause of death (even though all had HF)
217	with an adjusted OR of 0.32 (95% CI 0.23-0.43; p<0.001) accounting for age, sex, substance use,
218	and comorbidities.
219	Autopsy data were available for 81 individuals (14 PWH), who died between 2011 and
220	2019 in San Francisco County, 51 of whom were adjudicated as part of the POST SCD Study. Of
221	PWH, 4 (29%) met the WHO definition for presumed sudden cardiac death, which excludes
222	those with obvious external cause of death such as trauma or drug paraphernalia at the scene
223	(11), compared to 38 (56.8%) of those without HIV (p=0.08). Among these presumed SCDs,
224	PWH had a trend towards fewer adjudicated arrhythmic causes (21.4% vs 41.8%, p=0.23), and

225 more non-cardiac causes (78.6% vs 50.8%; p=0.08), including occult overdose with toxicology

Durstenfeld et al. HIV & HF Phenotypes and Outcomes in a Safety Net System

evidence without evidence of drug use at the scene (64.3% vs 37.8% of noncardiac deaths;
p=0.12).

228 Discussion

In this 18-year study of people with HF within a municipal safety-net system, PWH had a 229 greater all-cause mortality despite lower odds of hospitalization for HF, more often due to non-230 cardiovascular causes, especially overdose. PWH developed HF a mean 10 years younger than 231 people without HIV, with higher rates of documented substance use. HFrEF was more 232 233 commonly diagnosed in PWH, but echocardiographic and angiographic findings were similar 234 compared to cases without HIV. Although the mortality gap has narrowed over time, PWH with HF remain at elevated risk compared to people with HF without HIV. These findings have 235 236 implications for targeted strategies to reduce higher mortality in HF for PWH.

237 Similar Associations with Mortality as Compared to Prior Studies

238 Several prior studies have examined the association of HIV with HF outcomes in very different patient populations. A study of U.S. Veterans from 1999-2018 that included 5,747 239 PWH and 33,497 controls found higher mortality and hospitalizations among PWH, but the main 240 limitation is that they included 98% men (2,7). They also found that PWH develop HFrEF at 241 younger ages (2). Because the VA study focused on men, another study included ambulatory 242 women within the Partners HealthCare System (now Mass General Brigham) with a primary 243 outcome of incident HF hospitalization (5). Another study included patients hospitalized with 244 acute decompensated HF at Bronx-Lebanon Hospital Center in New York in 2011 with primary 245 246 outcomes of 30-day readmissions and mortality (6). These studies within tertiary referral centers both found that HIV is associated with HF hospitalization, in contrast to our findings. Our 247

findings are most consistent with a study within the Kaiser integrated care system, where HIV
was associated with mortality but not HF hospitalizations or Emergency Department visits, (8).
Our study extends these findings to the safety-net where many PWH in the United States receive
care.

Our study sheds light on a possible explanation for higher mortality among PWH with 252 253 HF. From 2000-2009, presumed sudden cardiac death (SCD) accounted for 86% of cardiac deaths among PWH in San Francisco, and antecedent HF was strongly associated with SCD (12). 254 Among these individuals, lower LVEF and diastolic dysfunction were both associated with 255 256 increased risk of SCD (13). In California from 2005-2015, PWH had 2.5-fold higher risk of out of hospital cardiac arrest (14). One group estimated that the risk of SCD was 10% per year 257 among PWH without indications for primary prevention implantable cardioverter-defibrillators 258 (15). We found very low use of defibrillators, much lower than would be expected for the 259 260 proportion with severely reduced LVEF. A population-based autopsy study in San Francisco 261 found that PWH were at 2.25 times higher risk of WHO-defined SCD, mostly attributable to higher rates of occult overdose, with 1.87 times higher incidence of arrhythmic death and 262 263 interstitial myocardial fibrosis on histology (16). Our finding that the primary cause of death is 264 most often attributed to HIV/AIDS suggests that many deaths are non-cardiac even among those with HF. Our findings that HIV is associated with higher risk of substance-related death are 265 266 confirmed in the autopsy subset and are likely attributable to higher rates of substance use among 267 PWH (17) as the association was attenuated accounting for documented substance use. Rising 268 rates of substance-associated cardiovascular death across the United States suggest that this 269 growing problem extends to the general population without HIV (18).

Durstenfeld et al. HIV & HF Phenotypes and Outcomes in a Safety Net System

270	One potential explanation for lower rates of HF hospitalization specific to the study
271	population may be that PWH may be better connected to ambulatory care within the municipal
272	health system in San Francisco compared to people without HIV, as demonstrated by the higher
273	rates of ambulatory follow-up after HF hospitalization. This may be in part due to the established
274	HIV Cardiology Clinic that is embedded within the main HIV primary care clinic at San
275	Francisco General Hospital. Secondly, among those hospitalized with HFrEF, PWH had higher
276	prescription rates for guideline directed medical therapy compared to people without HIV.
277	Although not conclusive, our study suggests that access to cardiology care does not fully address
278	the increased risk among PWH.
279	How can we mitigate the increased risk of mortality among PWH with HF? Prevention of
280	myocardial infarction with statins may decrease atherosclerosis and ultimately reduce incident
281	HF among PWH. Earlier detection of Stage B HF (asymptomatic structural heart disease) among
282	PWH could allow for initiation of disease-modifying medical therapy. Biomarkers could identify
283	those at elevated risk (19,20). The MIRACLE HIV trial randomized 40 PWH without known
284	heart disease (Stage A: asymptomatic with risk factors) 1:1 to eplerenone and placebo for 12
285	months and found that it prevented worsening of myocardial perfusion and function (21). Animal
286	models suggest that immune therapy targeting inflammation may prevent cardiomyopathy (22),
287	although this has not been tested in humans. Most important, however, may be providing high-
288	quality HIV and primary care to PWH even among those with HF, with particular attention to
289	substance use treatment and overdose prevention.

290 Limitations

The major limitation of this observational EHR-based study is the risk of residual
 confounding which limits causal interpretation—PWH may differ from those without HIV in
 Durstenfeld et al. HIV & HF Phenotypes and Outcomes in a Safety Net System

293 ways that affect HF outcomes not captured in billing codes. Some covariates are notably 294 imperfect such as unstable housing and substance use; other socioeconomic variables including 295 income, education, primary language, immigration status, and current housing were not measured. Secondly, we did not have time-updated covariates, so we used baseline covariates 296 assessed at the time of HF diagnosis. Ambulatory medication data were only available for those 297 298 who were hospitalized through medication reconciliation, so we were unable to assess use of 299 antiretroviral therapy or titration of GDMT. Previous studies have suggested that ICD coding has 300 a low specificity for HF (23), but in our system manual adjudication demonstrated a high 301 specificity. Emergency department and urgent care visits and specialty provider type for inpatient physicians were not available, limiting our ability to assess acute care utilization. 302 Finally, recorded cause of death is a poor measure of actual cause of death, but we confirmed our 303 findings by linking records with the postmortem data available in the POST SCD Study. 304

305 Conclusions

Among people with HF who receive care within a municipal safety-net system, HIV is 306 associated with higher all-cause mortality but not HF hospitalization. In the current era of 307 antiretroviral therapy, HF phenotypes between those with and without HIV are similar, although 308 PWH develop heart failure a decade younger and are more likely to present with HFrEF. As 309 recorded on death certificates and found on autopsy, non-cardiovascular causes of death 310 311 including substance-related, and HIV/AIDS deaths are predominant among PWH. Further research is needed to identify and test strategies to mitigate the increased risk of mortality among 312 PWH with HF including addressing high rates of substance use and treatment of HIV. 313

314

Durstenfeld et al. HIV & HF Phenotypes and Outcomes in a Safety Net System

315 **References**

- Butt AA, Chang CC, Kuller L et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011;171:737-43.
- Freiberg MS, Chang CH, Skanderson M et al. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection
 Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiol 2017;2:536-546.
- 323 3. Womack JA, Chang CC, So-Armah KA et al. HIV infection and cardiovascular disease in
 women. J Am Heart Assoc 2014;3:e001035.
- 4. Erqou S, Lodebo BT, Masri A et al. Cardiac Dysfunction Among People Living With
 HIV: A Systematic Review and Meta-Analysis. JACC: Heart Failure 2019;7:98-108.
- Janjua SA, Triant VA, Addison D et al. HIV Infection and Heart Failure Outcomes
 in Women. J Am Coll Cardiol 2017;69:107-108.
- Alvi RM, Afshar M, Neilan AM et al. Heart failure and adverse heart failure outcomes
 among persons living with HIV in a US tertiary medical center. Am Heart J 2019;210:3948.
- Frqou S, Jiang L, Choudhary G et al. Heart Failure Outcomes and Associated Factors
 Among Veterans With Human Immunodeficiency Virus Infection. JACC Heart Fail
 2020;8:501-511.
- 8. Avula HR, Ambrosy AP, Silverberg MJ et al. Human immunodeficiency virus infection
 and risks of morbidity and death in adults with incident heart failure. Eur Heart J Open
 2021;1:oeab040.
- 338 9. Tseng ZH, Olgin JE, Vittinghoff E et al. Prospective Countywide Surveillance and
 339 Autopsy Characterization of Sudden Cardiac Death: POST SCD Study. Circulation
 340 2018;137:2689-2700.
- Haghighat L, Ramakrishna S, Salazar JW et al. Homelessness and Incidence and Causes
 of Sudden Death: Data From the POST SCD Study. JAMA Intern Med 2023;183:13061314.
- Marijon E, Narayanan K, Smith K et al. The Lancet Commission to reduce the global
 burden of sudden cardiac death: a call for multidisciplinary action. Lancet 2023;402:883936.
- Tseng ZH, Secemsky EA, Dowdy D et al. Sudden cardiac death in patients with human
 immunodeficiency virus infection. J Am Coll Cardiol 2012;59:1891-6.
- Moyers BS, Secemsky EA, Vittinghoff E et al. Effect of left ventricular dysfunction and
 viral load on risk of sudden cardiac death in patients with human immunodeficiency
 virus. Am J Cardiol 2014;113:1260-5.
- 352 14. Sardana M, Nah G, Hsue PY et al. Human Immunodeficiency Virus Infection and Outof-Hospital Cardiac Arrest. Am J Cardiol 2022;163:124-129.
- Alvi RM, Neilan AM, Tariq N et al. The Risk for Sudden Cardiac Death Among Patients
 Living With Heart Failure and Human Immunodeficiency Virus. JACC Heart Fail
 2019;7:759-767.
- Tseng ZH, Moffatt E, Kim A et al. Sudden Cardiac Death and Myocardial Fibrosis,
 Determined by Autopsy, in Persons with HIV. N Engl J Med 2021;384:2306-2316.

359	17.	West BS, Diaz JE, Philbin MM, Mauro PM. Past-year medical and non-medical opioid
360		use by HIV status in a nationally representative US sample: Implications for HIV and
361		substance use service integration. J Subst Use Addict Treat 2023;147:208976.
362	18.	Minhas AMK, Kewcharoen J, Hall ME et al. Temporal Trends in Substance Use and
363		Cardiovascular Disease-Related Mortality in the United States. J Am Heart Assoc
364		2024;13:e030969.
365	19.	Secemsky EA, Scherzer R, Nitta E et al. Novel Biomarkers of Cardiac Stress,
366		Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC Heart
367		Fail 2015;3:591-9.
368	20.	Scherzer R, Shah SJ, Secemsky E et al. Association of Biomarker Clusters With Cardiac
369		Phenotypes and Mortality in Patients With HIV Infection. Circ Heart Fail
370		2018;11:e004312.
371	21.	Srinivasa S, Walpert AR, Thomas TS et al. Randomized Placebo Controlled Trial to
372		Evaluate Effects of Eplerenone on Myocardial Perfusion and Function among Persons
373		with HIV-Results from the MIRACLE HIV Study. Clin Infect Dis 2023.
374	22.	Yearley JH, Mansfield KG, Carville AA et al. Antigenic stimulation in the simian model
375		of HIV infection yields dilated cardiomyopathy through effects of TNFalpha. Aids
376		2008;22:585-94.
377	23.	Steverson AB, Pawlowski AE, Schneider D et al. Clinical characteristics of HIV-infected
378		patients with adjudicated heart failure. Eur J Prev Cardiol 2017;24:1746-1758.
379		

381

Table 1. Study Population by HIV Status

	HIV	No HIV	P-value
	(n=697)	(n=14,132)	
Age, years	52.8 (45.6, 59.1)	62.8 (53.4, 75.1)	< 0.001
Female	137 (19.7%)	5718 (40.9%)	< 0.001
Race/Ethnicity			< 0.001
White	259 (37.2%)	3748 (26.5%)	
Black/African American	310 (44.5%)	3820 (27.0%)	
Asian	23 (3.3%)	3153 (22.3%)	
American Indian/Alaskan Native	10 (1.4%)	148 (1.0%)	
Native Hawaiian/ Pacific Islander	0 (0.0%)	47 (0.3%)	
Hispanic/Latino	81 (11.6%)	2727 (19.3%)	
Other/Decline to state	14 (2.0%)	489 (3.5%)	
Documented Unstable Housing	50 (7.2%)	611 (4.3%)	< 0.001
Past Medical History			
Hypertension	503 (72.2%)	11413 (80.8%)	< 0.001
Diabetes	43 (6.2%)	1204 (8.5%)	0.03
Myocardial Infarction	84 (12.1%)	2072 (14.7%)	0.06
Chronic Kidney Disease	118 (16.9%)	2085 (14.8%)	0.11
COPD	18 (2.6%)	106 (0.8%)	< 0.001
Hepatitis C Virus	370 (53.1%)	1686 (11.9%)	< 0.001
Hepatitis B Virus	90 (12.9%)	420 (3.0%)	< 0.001
Documented Substance Use			

Alcohol	270 (38.7%)	2897 (20.5%)	<0.082
Tobacco	452 (64.8%)	5651 (40.0%)	<0.001
Opioid	235 (33.7%)	1351 (9.6%)	<0.001 385
Cocaine	265 (38.0%)	1826 (12.9%)	<0.001 386
Methamphetamine	285 (40.9%)	1477 (10.5%)	<0.0007
Heart Failure Guideline Directed N	<i>Medical Therapy</i> ^a		388
Beta Blocker	20 (54.1%)	371 (40.1%)	0.09
ACE inhibitor or Angiotensin	19 (51.4%)	382 (41.3%)	0.22 391
Receptor Blocker			392
Mineralocorticoid Receptor	10 (27.0%)	171 (18.5%)	0.19893
Antagonist			394
Angiography Results ^b			395
No Coronary Artery Disease	40 (28.6%)	564 (20.8%)	0.17 397
Nonobstructive Disease	44 (31.4%)	912 (33.6%)	
Single Vessel Disease	22 (15.7%)	454 (16.7%)	
Multivessel Disease	34 (24.3%)	784 (28.9%)	

398

^aHeart Failure Guideline Directed Medical Therapy was assessed at the time of index hospital
 discharge only and includes those with a heart failure hospitalization and HFrEF (left ventricular
 ejection fraction <40%): Denominators are 37 PWH and 925 people without HIV.

^bAngiography results are from the first coronary angiogram available and include n=140 PWH
 and n=2714 people without HIV without prior revascularization. Multivessel disease was defined

404 as left main stenosis reported as \geq 50% or 2 or more major epicardial vessels with \geq 80% stenosis.

405	Table 2. Echocardi	iographic Findin	gs Among those	Who Compl	leted an Echocardi	ogram
-----	--------------------	------------------	----------------	-----------	--------------------	-------

Finding	HIV (n=593)	No HIV	P-value
		(n=10579)	
Echo within 30 days of diagnosis	313 (52.8%)	5968 (56.4%)	0.08
Echo within 6 months of diagnosis	373 (62.9%)	7099 (67.1%)	0.03
HFrEF ^a	225 (37.9%)	3459 (32.7%)	0.008
First EF After HF Diagnosis, %	45.7 (15.7)	44.4 (15.6)	0.13
LV Inner Diameter at End Diastole, cm	5.1 (0.9)	5.0 (1.0)	0.20
Qualitative LV Function			
Hyperdynamic	11 (2.2%)	156 (1.7%)	0.59
Normal	214 (42.7%)	4010 (44.2%)	
Borderline	22 (4.4%)	439 (4.8%)	
Mildly Reduced	47 (9.4%)	842 (9.3%)	
Mild to Moderately Reduced	17 (3.4%)	320 (3.5%)	
Moderately Reduced	50 (10.0%)	779 (8.6%)	
Moderate to Severely Reduced	23 (4.6%)	603 (6.6%)	
Severely Reduced	115 (23.0%)	1879 (20.7%)	
Not reported	2 (0.4%)	46 (0.5%)	
Regional Wall Motion Abnormalities	71 (31.1%)	1023 (34.3%)	0.33
Pulmonary Hypertension			
Severe Pulmonary Hypertension	7 (2.2%)	176 (2.9%)	0.46
PASP, mm Hg, mean (SD)	37.1 (16.8)	36.9 (15.4)	0.85
Valve Disease ^b			

Severe Mitral Regurgitation	33 (10.5%)	406 (6.8%)	0.01
Severe Tricuspid Regurgitation	35 (11.2%)	509 (8.5%)	0.10
Endocarditis	5 (0.7%)	54 (0.4%)	0.17

406 Notes: a. HFrEF defined as LVEF<40% or for those missing LVEF, qualitative LV function at

407 least moderately reduced. b. Fewer than 1% in each group had severe aortic stenosis, severe

408 a ortic regurgitation, and severe mitral stenosis with no differences by group so we did not

- 409 include them in the table. Abbreviations: HFrEF=Heart Failure with Reduced Ejection Fraction;
- 410 EF=Ejection Fraction; LV=Left Ventricular

411



413 Central Illustration. Kaplan-Meier and Adjusted Survival Plots by HIV

414

Figure Legend: Age and sex adjusted survival curves for people with and without HIV from

416 index time of heart failure diagnosis up to 15 years of follow up (main figure) and from 0-12

417 months (inset). Survival curves separate about 3 months after HF diagnosis (inset), with an

418 adjusted hazard ratio of 1.55 (95% CI 1.37-1.76; p<0.0001).

Figure 1. Primary Underlying Cause of Death among People with Heart Failure as Recorded on Death Certificates by HIV Status



- 423 Figure Legend: Primary underlying cause of death as reported on death certificates classified by
- 424 International Classification of Diseases (ICD) codes by HIV status. Liver disease is classified
- 425 under gastrointestinal diseases.